Projects per year
Personal profile
Area of Expertise
The O’Bryant laboratory is dedicated to precision medicine in Alzheimer’s disease and other neurodegenerative diseases, including Down syndrome, Lewy Body disease, Parkinson’s disease, traumatic brain injury, and others. The fully translational lab has a Biomarker Core (Dr. Hall, Director), Clinical Core (Dr. Johnson, Director), Administrative Core (Dr. O’Bryant, Director) and Data Core (Dr. Johnson, Director). The lab also has a Neuroimaging Core (USC, Dr. Toga, Director). Dr. O’Bryant's multiple NIH grants focus on novel strategies for disease detection, screening into trials (therapeutic and prevention), and patient stratification for optimal treatment response. As part of this work, the lab has a strong focus on the impact of ethnicity/diversity on cognitive loss during the aging process and runs the one-of-a-kind Health & Aging Brain among Latino Elders (HABLE) study, which is the most comprehensive study of Mexican-American brain aging to date.
Education/Academic qualification
BS in Psychology, Louisiana State University
MA in Clinical Psychology, University at Albany
PhD in Clinical Psychology, University at Albany
Fingerprint
Dive into the research topics where Sid O'Bryant is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
The Health & Aging Brain Study - Health Disparities (HABS-HD)
O'Bryant, S., Johnson, L., TOGA, A., YAFFE, K. & RISSMAN, R.
30/09/22 → 31/08/23
Project: Research
-
-
-
-
-
Association of cardiovascular risk factors and blood biomarkers with cognition: The HABS-HD study
The Health and Aging Brain Study (HABS-HD) Study Team, 1 Jan 2023, In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 15, 1, e12394.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study
Alzheimer's Biomarker Consortium-Down Syndrome & Dominantly Inherited Alzheimer Network, Jan 2023, In: The Lancet Neurology. 22, 1, p. 55-65 11 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Comparison of genetic and health risk factors for mild cognitive impairment and Alzheimer's disease between Hispanic and non-Hispanic white participants
the Health and Aging Brain Study (HABS-HD) Study Team, Alzheimer's Disease Neuroimaging Initiative, 2023, (Accepted/In press) In: Alzheimer's and Dementia.Research output: Contribution to journal › Article › peer-review
Open Access -
Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice
for the HABS-HD Study Team, Jan 2023, In: Alzheimer's and Dementia. 19, 1, p. 36-43 8 p.Research output: Contribution to journal › Article › peer-review
5 Scopus citations -
Plasma Biomarkers of Alzheimer's Disease Are Associated with Physical Functioning Outcomes Among Cognitively Normal Adults in the Multiethnic HABS-HD Cohort
HABS-HD Study Team, 26 Jan 2023, In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 78, 1, p. 9-15 7 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations